Triple negative breast cancer treatment options and limitations: future outlook
O Obidiro, G Battogtokh, EO Akala - Pharmaceutics, 2023 - mdpi.com
Triple negative breast cancer (TNBC) has a negative expression of estrogen receptors (ER),
progesterone receptors (PR), and human epidermal growth factor receptors (HER2). The …
progesterone receptors (PR), and human epidermal growth factor receptors (HER2). The …
Pathology of triple negative breast cancer
F Borri, A Granaglia - Seminars in cancer biology, 2021 - Elsevier
Triple negative breast cancer (TNBC) is a subtype of breast tumor lacking hormone
receptors expression and HER2 gene amplification and represents 24% of newly diagnosed …
receptors expression and HER2 gene amplification and represents 24% of newly diagnosed …
[HTML][HTML] Genetic markers in triple-negative breast cancer
Z Sporikova, V Koudelakova, R Trojanec… - Clinical breast cancer, 2018 - Elsevier
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancer cases and
is characterized by the absence of estrogen, progesterone, and human epidermal growth …
is characterized by the absence of estrogen, progesterone, and human epidermal growth …
Endocrine resistance in breast cancer–an overview and update
Tumors that express detectable levels of the product of the ESR1 gene (estrogen receptor-α;
ERα) represent the single largest molecular subtype of breast cancer. More women …
ERα) represent the single largest molecular subtype of breast cancer. More women …
[HTML][HTML] Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
L Gerratana, D Basile, G Buono, S De Placido… - Cancer treatment …, 2018 - Elsevier
Triple negative breast cancer (TNBC) represents the 15–20% of all breast cancers (BC) and
is characterized by a very aggressive behavior. Recent data suggest that TNBC is not a …
is characterized by a very aggressive behavior. Recent data suggest that TNBC is not a …
Treatment strategies against triple-negative breast cancer: an updated review
Triple-negative breast cancer (TNBC) is associated with an increased risk of early
recurrence and distant metastasis, as well as the development of therapeutic resistance and …
recurrence and distant metastasis, as well as the development of therapeutic resistance and …
[HTML][HTML] A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer
Background Triple-negative breast cancer (TNBC) is a heterogeneous, aggressive
phenotype of breast cancer with associated chemoresistance. The development of chemo-or …
phenotype of breast cancer with associated chemoresistance. The development of chemo-or …
[HTML][HTML] Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression …
Background Triple-negative breast cancer (TNBC) represents up to 20% of all breast
cancers. This cancer lacks the expression of the estrogen receptor, progesterone receptor …
cancers. This cancer lacks the expression of the estrogen receptor, progesterone receptor …
[HTML][HTML] Breast cancer molecular subtypes: from TNBC to QNBC
Abstract Treatment protocols for breast cancer depend predominantly on receptor status with
respect to estrogen (estrogen receptor alpha), progesterone (progesterone receptor) and …
respect to estrogen (estrogen receptor alpha), progesterone (progesterone receptor) and …
Newly developed targeted therapies against the androgen receptor in triple-negative breast cancer: A review
Among different types of breast cancers (BC), triple-negative BC (TNBC) amounts to 15% to
20% of breast malignancies. Three principal characteristics of TNBC cells are (i) extreme …
20% of breast malignancies. Three principal characteristics of TNBC cells are (i) extreme …